Sandbox Reserved 430: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
P2Y12 is a G-protein-coupled receptor (GPCR) found on blood platelets. As a GPCR, P2Y12 responds to concentrations of adenosine diphosphate in the extracellular matrix. This leads to purinergic signal transduction and ultimately cellular response. Being located on blood platelets, activated P2Y12 receptors induce platelet activation and clotting. Drugs, such as clopidogrel, ticagrelor, and ticlopidine, are designed to inhibit P2Y12 activation by altering the receptor active site through secondary and tertiary structure modification. Successful inhibition of P2Y12 corresponds to decreased platelet activation, a helpful tool in prevention of stroke and heart attacks. Additionally, P2Y12-specific drugs can be used in treating cardiovascular disease. | P2Y12 is a G-protein-coupled receptor (GPCR) found on blood platelets. As a GPCR, P2Y12 responds to concentrations of adenosine diphosphate in the extracellular matrix. This leads to purinergic signal transduction and ultimately cellular response. Being located on blood platelets, activated P2Y12 receptors induce platelet activation and clotting. Drugs, such as clopidogrel, ticagrelor, and ticlopidine, are designed to inhibit P2Y12 activation by altering the receptor active site through secondary and tertiary structure modification. Successful inhibition of P2Y12 corresponds to decreased platelet activation, a helpful tool in prevention of stroke and heart attacks. Additionally, P2Y12-specific drugs can be used in treating cardiovascular disease. | ||
Here, image analysis of P2Y12 crystals are used to model protein structure in complex with AstraZeneca’s novel ADZ1283: Ethyl 6-(4(-((benzylsulphonyl)carbamoyl)piperidin-1yl)-5-cyano-2-methylnicotinate. ADZ1283 functions to block the P2Y12 receptor as a means to treat thrombosis. ADZ1283-binding leads to unique protein structure, unfound in other P2Y receptors. Helix V of seven transmembrane helices is found to be elongated and straightened. This change along with the discovery of a potential second active within P2Y12 has implications on how P2Y12 uses it’s seven transmembrane helical bundle interact with ADP in the bloodstream. | Here, image analysis of P2Y12 crystals are used to model protein structure in complex with AstraZeneca’s novel ADZ1283: Ethyl 6-(4(-((benzylsulphonyl)carbamoyl)piperidin-1yl)-5-cyano-2-methylnicotinate. ADZ1283 functions to block the P2Y12 receptor as a means to treat thrombosis. ADZ1283-binding leads to unique protein structure, unfound in other P2Y receptors. Helix V of seven transmembrane helices is found to be <scene name='48/483887/Elongated_and_straightened/3'>elongated and straightened</scene>. This change along with the discovery of a potential second active within P2Y12 has implications on how P2Y12 uses it’s seven transmembrane helical bundle interact with ADP in the bloodstream. | ||
<scene name='48/483887/Here_is/1'>Here is</scene> a view of the Anionic Side Chains in red and charged nucleic acids and ligands in grey. | <scene name='48/483887/Here_is/1'>Here is</scene> a view of the Anionic Side Chains in red and charged nucleic acids and ligands in grey. | ||
